The Cell and Gene Therapy Catapult and pHion Therapeutics announced an exclusive licence agreement for pHion’s proprietary RALA technology for ex-vivo applications. The agreement builds upon the ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 6 presentations offering insights into the research and development of ...

India witnessing sharp surge in cases of diabetes across all age brackets: Dr Vijay D’Silva: Our Bureau, Mumbai Saturday, October 4, 2025, 14:30 Hrs [IST] Branded the “diabete ...

Sitryx Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, announced it has received clearance ...

Draig Therapeutics to initiate phase 2 study of DT-101 for treatment of major depressive disorder: Cardiff, UK Saturday, October 4, 2025, 18:00 Hrs [IST] Draig Therapeutics (Draig ...

MMS, an award-winning and data-focused clinical research organization, has announced its role in the creation and release of one of the world’s largest proteomic datasets for neurodegenerative disease ...

AAVantgarde receives US FDA orphan drug designation & UK CTA approval for AAVB-039 to treat Stargardt disease: Milan Saturday, October 4, 2025, 17:00 Hrs [IST] AAVantgarde Bio (AA ...

Indian Pharmaceutical Alliance appoints Dr Sharvil Patel as president and Glenn Saldanha as vice president: Our Bureau, Mumbai Saturday, October 4, 2025, 14:15 Hrs [IST] The India ...

Global pharma major Lupin Limited (Lupin) announced the launch of liraglutide injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen, in the United States. Liraglutide injection, 18 mg/3 mL ...

Even as the Central Drugs Standard Control Organisation's (CDSCO) found that the cough syrup samples it tested from Madhya Pradesh free from diethylene glycol (DEG) or ethylene glycol (EG), samples of ...

Illumina, Inc., a global genomics and human health leader innovating the future of precision health, announced the launch of BioInsight, a new business within Illumina, developed to meet industry ...

EMA is advising marketing authorisation holders to submit individual type IA and type IAIN variations and super-groupings for 2025 no later than 21st November, 2025. This will enable EMA to ...